版本:
中国

BRIEF-FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for prophylaxis of attacks in patients with acute hepatic porphyria

May 31 Alnylam Pharmaceuticals Inc

* FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for the prophylaxis of attacks in patients with acute hepatic porphyria

* Company plans to initiate phase 3 clinical program in late 2017

* ‍Updated results from trial to be provided in oral presentation on June 26 at International Congress On Porphyrins and Porphyrias​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐